Valeo Pharma (VPH) Stock Price, News & Analysis

Company Overview

Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: C$0.05 to C$0.08
• 52-Week Range: N/A
• Volume: 51,000 shs
• Average Volume: 59,093 shs
• Market Capitalization: C$4.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VPH Stock Analysis - Frequently Asked Questions

How were Valeo Pharma's earnings last quarter?

Valeo Pharma Inc. (TSE:VPH) issued its quarterly earnings results on Thursday, September, 12th. The company reported ($0.08) earnings per share (EPS) for the quarter. The firm earned $12.60 million during the quarter.

How do I buy shares of Valeo Pharma?

Shares of VPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Valeo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Valeo Pharma investors own include Fission Uranium (FCU), Pasithea Therapeutics (KTTA), Pure Gold Mining (PGM), Quarterhill (QTRH), Skye Bioscience (SKYE), Skye Bioscience (SKYE) and Wave Life Sciences (WVE).

Company Calendar

• Last Earnings: 9/12/2024
• Today: 11/21/2024
• Next Earnings (Estimated): 2/03/2025

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:VPH
• CUSIP: N/A
• CIK: N/A
• Web: www.valeopharma.com
• Phone: 514-694-0150
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-32,120,000.00
• Net Margins: -60.18%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -26.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.27
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: C$53.38 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: C($0.64) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 98,660,000
• Free Float: N/A
• Market Cap: C$4.44 million
• Optionable: Not Optionable
• Beta: 2.32